Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Ziconotide for Refractory Pain in Cancer or AIDS
NCT00002160Phase 2Completed
- Sponsor
- Neurex Corporation
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic pain comparing Ziconotide with Placebo (2 arms). Primary endpoint: Mean percentage change in Visual Analog Scale of Pain Intensity score. Status: completed.
02
Drugs
ziconotide
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT00002160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002160.